Novel Design of Nanotechnology to Deliver Promising Result in the Treatment of Cancer

Release Date: 24-Nov-2020

Novel study focused towards nanotechnology is estimated to deliver targeted as well as personalized vaccines into the cancer patients. As per the research conducted, the utilization of charged nanoscale metal-organic frameworks for generating free radicals using X-rays present in the cancer tissue can kill the cancer cells without any side effects. It is witnessed that similar framework can be used in delivering some of the immune signaling molecules known as PAMPs to the activation of immune response against cancer cells. The combination of the above-mentioned approaches is estimated to deliver a vaccine that could treat local as well as systemic cancer.


The whole research work is focused on using the properties of nanoscale metal organic framework for the development of the nanoparticles capable of infiltrating tumors. It is estimated that the lattice like structure of the nanoparticle could be used for efficient deliver of the cancer drugs at the site of tumor. The researchers loaded the lattice-like structure with drugs such as pathogen-associated molecular patterns. It was analyzed by the researchers that the nanoparticles that were applied to the cancer cells had double effect. It was able to produce antigens against the tumor, released the PAMPs as well as generated a strong immune response against the cancer cells.


Further experiments of the nanoparticle developed were done for immune checkpoint inhibitors, which indeed also was successful in delivering novel hopes to the researchers and the patients. It is witnessed that the future work of the clinical research study will be inclined towards re-defining the design so that better clinical outcomes could be generated. The future formulation of the therapy is estimated to zoom to maximum opportunities that are related with it so that cancer patients could receive healthcare benefits.

Need custom market research solution? We can help you with that too.